Displaying drugs 7951 - 7975 of 8090 in total
Vitespen
Investigational
RG-7795
Investigational
PRX-07034
Investigational
Cariporide
Investigational
TBC-3711
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Alicaforsen
Investigational
alpha-Conotoxin VC 1.1
Investigational
G4460
Investigational
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
Vasomera
Investigational
Methopterin
Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.
Investigational
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
AT-527
Investigational
Latiglutenase
Investigational
Epothilone D
Investigational
Morphine glucuronide
Investigational
Elvucitabine
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Refametinib
Investigational
TAS-108
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Displaying drugs 7951 - 7975 of 8090 in total